Roy A. Beveridge, MD
Keynote: Changing standards of evidence for assessing benefit/risk – learnings from other diseases and applicability to autoimmune diseases
Senior Vice President & Chief Medical Officer
Dr. Roy Beveridge is Humana’s Senior Vice President and Chief Medical Officer, where he is responsible for developing and implementing the company’s clinical strategy and advancing its integrated care delivery model. He is known for creating collaborative environments among physician communities and providing thought leadership, publishing extensively in the fields of medical oncology, quality design, ethics, and population health. Previously, Dr. Beveridge served as Chief Medical Officer for McKesson Specialty Health and as Executive VP and Chief Medical Officer for US Oncology. He practiced for more than 20 years in medical oncology and stem cell transplant in northern Virginia.
Jeffrey R. Curtis, MD MS MPH
Session 1: What is the available clinical evidence from RCTs, registries, and other sources to support biologic selection? | From the Perspective of Rheumatoid Arthritis
William J. Koopman Endowed Professor in Rheumatology and Immunology
Director, UAB Arthritis Clinical Intervention Program
Co-Director, UAB Center for Education and Research on Therapeutics (CERTS)
Co-Director, UAB PharmacoEpidEmiology and phaRmcoeconomics (PEER) Unit
University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology
Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.
Dr. Curtis currently holds the William J. Koopman Endowed Professorship in Rheumatology and Immunology at UAB. He is the Co-Director of the UAB Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders, which has a major emphasis on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. Additionally, as the Director of the UAB Arthritis Clinical Intervention Program, he leads the clinical trials unit for the rheumatology division at UAB, with a particular focus on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016.
The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network “Arthritis-Power” registry, focused on RA, psoriasis, and psoriatic arthritis. He also leads the multi-center NIH-funded large pragmatic randomized controlled trial “VERVE” studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents. He is a member of the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) Herpes Zoster workgroup. In 2015, he was appointed as a member to the FDA Arthritis Advisory Committee.
Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures.
Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), the American Medical Informatics Association (AMIA), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). He has authored more than 350 peer-reviewed manuscripts, review articles and book chapters.
Bruce E. Strober, MD, PhD
Session 1: What is the available clinical evidence from RCTs, registries, and other sources to support biologic selection? | From the Perspective of Psoriasis
Professor and Chair Department of Dermatology
Director, Clinical Trials Unit
University of Connecticut School of Medicine
Farmington, CT USA
Bruce E. Strober, MD, PhD, is Professor and Chair, and Director of the Clinical Trials Unit in the Department of Dermatology, University of Connecticut School of Medicine, in Farmington, Connecticut.
Dr. Strober earned both his medical degree and his doctorate from Columbia University College of Physicians and Surgeons in New York, New York. He completed his residency in dermatology in the Ronald O. Perelman Department of Dermatology, NYU School of Medicine. He is board certified by the American Board of Dermatology.
Dr. Strober’s research interests include the study of therapeutics, both old and new, for inflammatory skin disease, specifically interventions that help patients with difficult-to-treat psoriasis, atopic dermatitis, and hidradenitis suppurativa. Additional research interests include elucidation of novel features of inflammatory skin disease not previously uncovered and assisting in the clarification of the pathophysiology of inflammatory skin disease. He has served as principal investigator or subinvestigator for numerous multicenter clinical studies.
In his practice, Dr. Strober focuses on the treatment of difficult to treat inflammatory skin diseases that have tremendously negative impact on individuals’ quality of life.
Dr. Strober is on the Board and Secretary for the International Psoriasis Council, has served as a Section Editor for the British Journal of Dermatology, and is an ad hoc reviewer for Journal of the American Academy of Dermatology, Archives of Dermatology, British Journal of Dermatology, and Inflammation. He has published more than 120 book chapters and articles in peer-reviewed journals such as Archives of Dermatology, New England Journal of Medicine, Journal of the American Academy of Dermatology, and Journal of Investigative Dermatology, the Journal of the American Medical Association, among others.
Joshua Korzenik, MD
Session 1: What is the available clinical evidence from RCTs, registries, and other sources to support biologic selection? | From the Perspective of Inflammatory Bowel Disease (IBD)
Director of Crohn's and Colitis Center
Brigham and Women's Hospital of Harvard Medical School
Joshua R.. Korzenik is the director of the Brigham and Women’s Hospital Crohn’s and Colitis Center and assistant professor of medicine at Harvard Medical School. He was an undergraduate at Harvard University before receiving his M.D. from Albert Einstein College of Medicine in 1987. He completed internship and residency at Beth Israel Hospital in Boston, Massachusetts. After a period involved in clinical research in India, he completed his fellowship at Yale School of Medicine where he remained on faculty before going to Washington University in St Louis in 1997. He directed the Inflammatory Bowel Disease Center at Washington University in St Louis before coming to Massachusetts General Hospital where he co-directed the MGH IBD Center for a decade. He then moved to BWH to develop the BWH Crohn’s and Colitis, the leading IBD Center in New England a group of 8 physicians caring for over 3,500 individuals with IBD. He directs an extensive research program including clinical, epidemiologic and translational research focused on the microbiome and immunology to improve our understanding of the pathophysiology of the disease and better, innovative therapies ranging from novel biologic targets to fecal microbial transplants. A major effort is to develop and study new approaches to improve the delivery of care to people with IBD.
Steven Peskin, MD, MBA, FACP
Session 2: Perspective of key stakeholders on evidence requirements | From the Payer perspective
Executive Medical Director, Population Health, BCBSNJ
Associate Clinical Professor of Medicine, Rutgers RWJ Medical School
Dr. Steven R. Peskin is the Executive Medical Director, Population Health at Horizon Blue Cross Blue Shield of New Jersey. His expertise encompasses physician leadership, population health management, clinical and operational performance improvement in health care, medical education and scientific communications. He has been one of the driving forces for the creation of and successful maturation of value based models in New Jersey.
Dr. Peskin continues to work at the Rutgers Robert Wood Johnson School of Medicine as a clinical preceptor and instructor at the Eric B. Chandler Clinic and assists in the business of medicine curriculum. He is Course Director for Internal Medicine Grand Rounds at The University Medical Center in Princeton . He has held faculty appointments in medicine at several universities across the country and is currently an Associate Clinical Professor of Medicine Rutgers Robert Wood Johnson School of Medicine.
Or. Peskin received his bachelor's degree from The University of North Carolina Chapel Hill and medical degree from Emory University School of Medicine. He completed residency at Saint Elizabeth's Medical Center in Boston and holds an MBA from the Sloan School of Management at Massachusetts Institute of Technology.
Sumit Dutta, MD, MBA
Session 2: Perspective of key stakeholders on evidence requirements | From the PBM perspective
Senior Vice President, Chief Medical Officer
Sumit Dutta, M.D., currently serves as senior vice president, chief medical officer (CMO) for OptumRx. In this capacity, his primary responsibilities include executive level oversight of clinical strategy, leading the Clinical Services team and guiding its tactical and strategic endeavors to improve outcomes and lower overall health care costs.
Prior to his current position, he served as the CMO of Catamaran, one of the nation’s largest pharmacy benefit management (PBM) companies serving 35 million lives, which combined with OptumRx in 2015.
Before joining Catamaran, Dr. Dutta served as vice president/general manager for Quest Diagnostics’ India subsidiary, driving growth in the diagnostics, employer and clinical trials laboratory testing markets. He held various leadership roles at Medco, including CMO of Medco’s Health Plans business unit, responsible for clinical and utilization management products, account management, specialty pharmacy and provider strategy. He also served as senior vice president, Physician Strategy, as well as president of Accredo Nova Factor, Medco’s oral and self-injectable specialty business. During his career with Medco, Dr. Dutta led the development of industry leading utilization management programs, as well as a full range of clinical products and services.
Dr. Dutta earned his medical degree from Michigan State University and a Master of Business Administration from New York University, Stern School of Business. He completed his internship at the University of Chicago Hospitals and Clinics and residency at Rush Medical Center, practicing Internal Medicine at New York University Health Center.
Session 2: Perspective of key stakeholders on evidence requirements | From the Patient perspective
Ben has overseen all stages of PatientsLikeMe’s growth, including financing, expansion of patient communities and business partnerships and product strategy. Ben is a frequent speaker at conferences and an expert source for media on patient issues and patient-centered care. Previously, he served in manufacturing and business development roles at Target Therapeutics. Ben earned his bachelor’s degree in Mechanical Engineering from the Massachusetts Institute of Technology and his master’s degree in Business Administration from UCLA’s Anderson Graduate School of Management.
Dan Solomon, MD, MPH
Session 3: Review of data sources and gaps, and evidence for comparative and cost effectiveness going forward | Novel study designs to generate real-world evidence
Professor of Medicine and Chief of the Section Clinical Sciences
Division of Rheumatology at Brigham and Women’s Hospital (BWH)
Daniel H. Solomon, MD, MPH, is a Professor of Medicine and Chief of the Section Clinical Sciences in the Division of Rheumatology at Brigham and Women’s Hospital (BWH). He holds the Matthew H. Liang Distinguished Chair in Arthritis and Population Health at BWH. Solomon has advanced the care and treatment of patients throughout his career, most notably with his investigative research achievements in the epidemiology of rheumatic diseases and the comparative effectiveness of treatments in this area.
Solomon earned his BA and MD degrees at Yale University, MPH at Harvard University and completed his residency in internal medicine and fellowship in rheumatology at BWH. His early work focused on the safety of NSAIDs and selective COX-2 inhibitors, and he continues to study analgesics. He has also examined osteoporosis prescribing in the US and conducted several large-scale trials to improve osteoporosis care.
Solomon’s research also has focused on cardiovascular disease in rheumatoid arthritis. He is the co-Principal Investigator on an NIH funded trial testing the effect of disease-modifying antirheumatic drugs (DMARDs) on cardiovascular disease.
He has published over 300 articles and has been PI on numerous NIH, foundation, and industry supported grants. He currently is the Deputy Editor of Arthritis & Rheumatology. As well, he is the Chair of the FDA Arthritis Advisory Committee.
In addition to his investigative achievements, Solomon has a busy clinical practice and has played a special role in helping the Hispanic community and been instrumental in advancing the collaborative clinical Cardiovascular in Rheumatology Medicine practice at BWH. Solomon has mentored over 30 trainees and junior faculty and was recently awarded The Baughman Faculty Mentoring Award at BWH.
Jim Harnett, PharmD, MS
Session 3: Review of data sources and gaps, and evidence for comparative and cost effectiveness going forward | Expansion of Real World Data from EMR and Claims: Strengths and Weaknesses
Analytical Science Lead in Real World Data and Analytics (RWDnA) Center of Excellence
Dr. James Harnett is an Analytical Science Lead in Real World Data and Analytics (RWDnA) Center of Excellence for Pfizer’s Patient and Health Impact organization. Dr. Harnett supported establishing the RWDnA function at Pfizer that drives collaboration and the timely development and delivery of tools, solutions and capabilities for the use of real world data and advanced analytics across the enterprise. Prior to his current position, Dr. Harnett was a Team Leader in Health Economics & Outcomes Research overseeing research programs across numerous therapeutic areas as well as establishing groundbreaking collaborations with payers and other healthcare stakeholders on joint research initiatives and long-term integrated health partnerships.
Dr. Harnett has worked with Pfizer for over 15 years creating and leading research programs in support of development and in-line products across therapeutic franchises including oncology, vaccines, inflammation and immunology, pain, women’s health, neurology, psychiatry, diabetes, urology, respiratory, and anti-infectives. He has extensive experience in working with US customers and supporting Global reimbursement and regulatory submissions. Dr. Harnett has authored over 30 peer-reviewed publications.
Dr. Harnett received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees at Rutgers, The State University of New Jersey. He received a Master of Science degree in Clinical Epidemiology and Health Services Research at Weill Cornell Graduate School of Medical Sciences.
Gary Kurtzman, MD
Session 3: Review of data sources and gaps, and evidence for comparative and cost effectiveness going forward | Artificial Intelligence and the Role of Machine Learning to Derive new Insights from Different Clinical Sources
Safeguard Scientifics (NYSE:SFE)
Gary Kurtzman, MD is Managing Director at Safeguard Scientifics (NYSE:SFE), which provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media.
Gary has more than 30 years of experience in operations and investments, leveraging his medical expertise to enable businesses to enhance their products and grow their services, as well as to discover new partnering potential in developing entrepreneurial companies.
Gary joined Safeguard in 2006, where he is responsible for identifying, deploying capital in and supporting emerging healthcare companies. Gary is a board member of MedCrypt (Chairman), Oncora Medical (Chairman) as well as Safeguard’s partner companies Aktana, meQuilibrium, Prognos (fka Medivo), Propeller Health, Syapse (Chairman) and Trice Medical (Chairman) and Zipnosis.
Throughout his career, Gary has realized value for companies through a series of successful IPOs, M&A and turnaround transactions. Specifically at Safeguard, Gary was accountable for the following successful exit transactions for Safeguard’s partner companies: Myriad Genetics’ acquisition of Crescendo Bioscience for $270 million, in cash; Becton, Dickinson’s acquisition of Alverix for $40 million; Shire Pharmaceuticals’ acquisition of Advanced BioHealing for $750 million, in cash; and Eli Lilly’s acquisition of Avid Radiopharmaceuticals for $300 million, up front, with an additional $500 million payout depended upon the achievement of future regulatory and commercial milestones.
Gary joined Safeguard from BioAdvance, a state initiative committed to funding early-stage life sciences companies, where he served as Managing Director and Chief Operating Officer. Previously, he was Chief Executive Officer at Pluvita Corporation, a company developing biological and bioinformatic solutions for drug and diagnostic development. Gary also previously served as Chief Operating Officer at Genovo, Inc., a gene therapy start-up company. He was also employed as head of research & development by Avigen, Inc., an early-stage gene therapy company located in San Francisco.
Gary began his career with Gilead Sciences, Inc.—at the time, a pre-IPO biotechnology company—as virology group leader. A board-certified internist from Barnes Hospital in St. Louis, MO, with a hematology sub-specialty, Gary has authored more than 40 research articles, book chapters and reviews, and is credited as inventor on twelve issued United States patents. Presently, Gary serves on various academic and biomedical committees and board.
Presently, Gary is a lecturer in the Health Care Management Department at the Wharton School at the University of Pennsylvania where he teaches entrepreneurship in life sciences.
Jeff Greenberg, MD, MPH
Moderator: Session 1
Chief Science Officer
Dr. Greenberg is Chief Scientific Officer with Corrona, and holds an appointment as Clinical Associate Professor of Medicine at New York University School of Medicine. Dr. Greenberg continues to see patients at the Institute for Rheumatic and Autoimmune Diseases at Overlook Hospital in New Jersey. Dr. Greenberg has published more than 100 peer-reviewed manuscripts, as well as textbook chapters, primarily focused on rheumatoid arthritis and psoriatic arthritis.
Moderator: Session 2
Ray has spent the majority of his career in the healthcare field - first as a consultant and then running several divisions and companies. In addition to his role as Chairman and CEO of Corrona, he is also Chairman of Prognos, a venture capital backed company that focuses on unlocking the power of lab data to improve treatment of patients. Previously Ray was President of InVentiv Clinical, a major player in the clinical research space. He has also served as CEO of PPD, and President of IMS Consulting and Services. He lives in Princeton NJ, and is Board Chair of Row New York, a non-profit that pairs rowing with rigorous academic support for underprivileged kids in New York City. Ray holds a BS from Cornell University, and an MEM from Duke University.
Joel Kremer, M.D.
Moderator: Session 3
Pfaff Family Professor of Medicine, Albany Medical College
Director of Research, The Center for Rheumatology, Albany, NY
Chief Medical Officer, Corrona
Joel Kremer graduated from Temple University School of Medicine where he was elected to Alpha Omega Alpha, and trained in Internal medicine and Rheumatology at Albany Medical Center Hospital, and Albany Medical College. He joined the faculty there in 1979, became a full professor in 1990 when he assumed the title of Head of the Division of Rheumatology there. In 2000, he became Director of Research at The Center for Rheumatology in Albany, NY. He is the Pfaff Family Professor of Medicine at the Albany Medical College.
His research interests have been in the area of therapeutics in patients with rheumatoid arthritis, as well as dietary intervention in this area. He has worked extensively on methotrexate and combinations of new agents when used with this drug. He is the recipient of the Engalaticheff Award given by The Arthritis Foundation for “contributions which improve the quality of life of patients with arthritis” in 1997, and is a 2013 Master of the ACR.
He is the author of approximately 200 peer-reviewed publications, 20 chapters and 6 texts. He is founder of the Corrona, LLC and CMO of the organization. He is President of the Corrona Research Foundation.